Sun Pharma settles patent litigation with Ironwood, Allergan
New Delhi: Drug major Sun Pharma said it has settled a patent litigation with Ironwood Pharmaceuticals Inc and Allergan plc in the US over a generic version of Linzess, a drug used to treat bowel problems.
The company's wholly-owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals and Allergan to resolve the patent litigation regarding submission of an abbreviated new drug application (ANDA) for a generic version of Linzess in the US, Sun Pharma said in a statement.
Under the terms of the settlement, Ironwood and Allergan will grant Sun Pharma subsidiaries a license to market a generic version of Linzess in the US beginning February 1, 2031, subject to USFDA approval or earlier under certain circumstances, it added.
As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and both the companies, regarding the Linzess patents, will be dismissed, Sun Pharma said.
The companies, however, did not share any additional details regarding the settlement.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd